Fig. 3: CLL sensitivity to TG02 correlated to its inhibition of CDK9 and reduction of Mcl-1. | Blood Cancer Journal

Fig. 3: CLL sensitivity to TG02 correlated to its inhibition of CDK9 and reduction of Mcl-1.

From: The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action

Fig. 3

A Immunoblots of pSer2 and total RNA pol II, Mcl-1 after 4 h incubation with TG02 in four CLL samples that varied in their sensitivity to TG02. Cell viabilities after 24 h incubation with TG02 were shown at the bottom of the blots. B Dose response of the 4 CLL samples to TG02 measured at 24 h. C TG02 IC50 correlated to the inhibition of RNA pol II phosphorylation and reduction of Mcl-1. PSer2-pol II and Mcl-1 level levels (at 0.3 μM TG02) were quantitated from the immunoblots, normalized to GAPDH, calculated as percentage of controls and correlated to the IC50s of TG02. R squared values were generated by linear regression.

Back to article page